Gujarat-based pharmaceutical packaging manufacturer Medicap Healthcare has reduced its proposed initial public offering (IPO) size by 29% to ₹170 crore from the earlier planned ₹240 crore. The company has also withdrawn its proposed ₹48 crore pre-IPO placement, revising the structure of its upcoming public issue through an addendum published on November 21, 2026.

The revised IPO will continue to comprise an entirely fresh issue of equity shares, with no offer-for-sale component. Medicap Healthcare plans to use the proceeds primarily to purchase machinery for its existing manufacturing facility and repay outstanding borrowings. The revised fundraising plan comes as the company prepares to expand its pharmaceutical packaging production capacity in Vadodara, Gujarat.

Medicap Healthcare Reduces IPO Size From ₹240 Crore to ₹170 Crore

According to the company’s November 21 addendum, Medicap Healthcare has reduced its proposed IPO size from ₹240 crore to ₹170 crore following a board resolution dated November 15, 2026.

The company has also decided not to proceed with the proposed pre-IPO placement of up to ₹48 crore that was included in its original draft offer structure.

The original fundraising plan, disclosed in September 2025, included a fresh issue of equity shares aggregating up to ₹240 crore. The company had reserved the option to raise up to ₹48 crore through a pre-IPO placement before the public offering.

The latest revision removes that placement component and reduces the overall size of the public issue.

IPO detailsOriginal proposalRevised proposal
Total IPO size₹240 crore₹170 crore
Proposed pre-IPO placementUp to ₹48 croreDropped
Offer for saleNilNil
Issue structureFresh issueFresh issue
Reduction in IPO size—Approximately 29.2%

The revised issue size is approximately 29.2% lower than the original proposal.

Why Has Medicap Healthcare Changed Its IPO Structure?

The revision is being made under applicable Securities and Exchange Board of India (SEBI) regulations.

According to the Moneycontrol report, issuers are permitted to increase or decrease the fresh issue size by up to 50% without filing a new draft red herring prospectus for IPOs opening on or before March 31, 2027, subject to the applicable regulatory conditions.

This allows Medicap Healthcare to revise its fundraising plans without restarting the entire draft filing process.

The company originally filed its draft IPO papers with SEBI in September 2025. The regulator approved the offer documents in January 2026.

The latest addendum updates the proposed issue structure and the allocation of the funds expected to be raised.

Where Will Medicap Healthcare Use the ₹170 Crore IPO Proceeds?

The company plans to allocate most of the net IPO proceeds towards expanding its manufacturing operations and reducing debt.

According to the revised proposal, the funds will be used for three primary purposes.

Use of IPO proceedsProposed allocation
Purchase of plant and machinery₹83 crore
Repayment of borrowings₹44 crore
General corporate purposesRemaining proceeds

The largest allocation, ₹83 crore, will be directed towards purchasing additional machinery for the company’s existing manufacturing facility.

Another ₹44 crore will be used to repay outstanding borrowings.

The remaining proceeds will support general corporate requirements.

The allocation indicates that Medicap Healthcare is prioritizing manufacturing expansion while also seeking to strengthen its balance sheet.

Medicap Healthcare Plans Major Manufacturing Capacity Expansion

Medicap Healthcare operates a manufacturing facility in Vadodara, Gujarat, where it produces pharmaceutical packaging products.

Its product portfolio includes Euro Head caps and bottle preforms, which are used in pharmaceutical packaging and related applications.

The company manufactures packaging components supplied to pharmaceutical businesses in domestic and international markets.

In FY26, Medicap Healthcare produced approximately 45 crore units against an installed annual production capacity of around 80 crore units at its existing facility.

This means the company operated at approximately 56.3% of its installed capacity based on the reported production figures.

The proposed expansion is expected to add another 96.6 crore units of annual production capacity.

The planned additions include:

  • 69.6 crore units: Additional capacity for pharmaceutical packaging caps and closures.
  • 27 crore units: Additional capacity for bottle preforms.
  • 96.6 crore units: Total proposed additional annual capacity.

The company plans to install 29 additional injection moulding machines at its existing manufacturing facility to support the expansion.

If implemented as planned, the expansion could significantly increase Medicap Healthcare’s manufacturing capabilities and provide additional capacity to serve pharmaceutical customers.

Company’s Outstanding Debt Stands at ₹244.9 Crore

Debt repayment is another important objective of the revised IPO.

As of November 15, 2026, Medicap Healthcare reported outstanding borrowings of approximately ₹244.9 crore on a consolidated basis.

Its standalone borrowings stood at approximately ₹36.2 crore.

The proposed allocation of ₹44 crore towards debt repayment could help reduce its financial obligations and interest costs.

However, the final impact will depend on which borrowings are repaid, their interest rates and the company’s future borrowing requirements.

The IPO’s debt-repayment component is particularly relevant because the company is simultaneously planning a major manufacturing expansion that will require additional investment.

Medicap Healthcare’s IPO Journey Began in September 2025

Medicap Healthcare initially filed its draft red herring prospectus with SEBI in September 2025, seeking to raise ₹240 crore through a fresh issue of equity shares.

The original proposal did not include an offer-for-sale component, meaning existing shareholders were not planning to sell shares as part of the public offering.

Aryaman Financial Services has been appointed as the sole book-running lead manager for the issue.

The company has not yet announced the final IPO opening date, price band, lot size or listing schedule in the reported revision.

Investors will need to wait for the updated offer documents and subsequent announcements for those details.

The Bigger Picture

Medicap Healthcare’s revised IPO highlights how companies can adjust their fundraising plans before entering the public markets.

Reducing the issue size does not necessarily indicate weaker business prospects. It can reflect changes in capital requirements, financing strategy, expansion priorities or market conditions.

For Medicap Healthcare, the revised plan continues to focus on two major objectives: increasing manufacturing capacity and reducing debt.

The pharmaceutical packaging industry also benefits from demand linked to medicine production, distribution and packaging requirements. As pharmaceutical manufacturers expand their operations, suppliers of caps, closures and bottle components can gain opportunities to increase production and customer relationships.

However, investors will need to evaluate the company’s financial performance, customer concentration, debt levels, manufacturing utilization and profitability before assessing the IPO.

Looking Ahead

The next important development will be the publication of Medicap Healthcare’s updated IPO documents and the announcement of its issue timeline, price band and other subscription details. Investors will also be watching whether the company successfully completes its planned machinery purchases and manufacturing expansion after raising capital through the public issue.

The revised ₹170 crore offering will give the company an opportunity to fund its expansion while reducing part of its outstanding debt. Whether the IPO attracts strong investor interest will depend on its valuation, financial performance, growth prospects and the broader conditions in India’s primary market.

Get the day’s top stories in your inbox

One concise email. No spam, unsubscribe anytime.